Alliance for Pandemic Preparedness

February 25, 2021

BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Category:

Topic:

Keywords (Tags):

In an observational study of the mass vaccination campaigns in Israel, real world effectiveness of the Pfizer vaccine 7 or more days after the second dose was 92% for documented SARS-CoV-2 infection, 94% for symptomatic infection, 87% for hospitalization, and 92% for severe disease. The study included 596,618 individuals matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics.

Vaccine effectiveness between 14 and 20 days after the first dose was 46%, 57%, 74%, 62%, and 72% in preventing any documented SARS-CoV-2 infection, symptomatic infection, hospitalization, severe disease, and death, respectively.

The estimated vaccine effectiveness in preventing any infection among studied sub-populations was consistent across age groups, with potentially lower effectiveness in individuals with multiple co-existing conditions.

Dagan et al. (Feb 24, 2021). BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2101765